"Sildenafil Citrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.
| Descriptor ID |
D000068677
|
| MeSH Number(s) |
D02.065.884.675 D02.886.590.700.675 D03.383.606.854 D03.633.100.759.824
|
| Concept/Terms |
Sildenafil Citrate- Sildenafil Citrate
- Citrate, Sildenafil
- 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
UK 92480-10- UK 92480-10
- UK 92480 10
- UK 9248010
- UK-92,480-10
- UK 92,480 10
|
Below are MeSH descriptors whose meaning is more general than "Sildenafil Citrate".
Below are MeSH descriptors whose meaning is more specific than "Sildenafil Citrate".
This graph shows the total number of publications written about "Sildenafil Citrate" by people in this website by year, and whether "Sildenafil Citrate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 5 | 5 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 5 | 5 |
| 2015 | 3 | 1 | 4 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sildenafil Citrate" by people in Profiles.
-
Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis. Cardiol Young. 2023 Nov; 33(11):2297-2311.
-
Evaluating the safety of intermittent intravenous sildenafil in infants with pulmonary hypertension. Pediatr Pulmonol. 2017 02; 52(2):232-237.
-
Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction. Dig Dis Sci. 2015 Nov; 60(11):3491-4.
-
Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med. 2002 Apr 15; 165(8):1098-102.